

# 510(k) Submissions Workshop

AdvaMed Office 1301 Pennsylvania Ave. N.W. Suite 400 Washington, D.C. February 3 – 4, 2025

<u>Feb 3, 2025</u>	
8:30 – 9:00 am	Registration Check-In and Continental Breakfast
9:00 – 9:05 am	Welcome and Introductions
9:05 – 10:30 am	<ul> <li>The Law and Regulations</li> <li>Sally Maher, Regulatory Consultant, Sally Maher Consulting <ul> <li>510(k) definition</li> <li>510 and 513 FDCA</li> </ul> </li> <li>Guidance for 510(k): general &amp; product specific <ul> <li>How to find it</li> <li>How to use it</li> </ul> </li> <li>Different types of 510(k)s; which to use</li> <li>Review of bundling 510(k)s</li> <li>FDA Product Codes – Activity</li> </ul>
10:30 – 10:45 am	Break
10:45 am – 12:00 pm	<ul> <li>510(k) Strategy and Planning</li> <li>Tony Blank, Senior Director of Regulatory Affairs, AtriCure <ul> <li>Staff involved</li> <li>Role of each function</li> <li>RA responsibilities</li> <li>Use of guidance</li> <li>Global considerations</li> <li>Pre-submissions</li> <li>Predicates</li> <li>Breakthrough Devices Program</li> <li>Safer Technologies Program</li> </ul> </li> </ul>
12:00 – 1:00 pm	Networking Lunch
1:00 – 2:15 pm	<ul> <li>Preparing the Submission</li> <li>Jemin Jay Dedania, Director of Regulatory Affairs, Global Regulatory, Hogan Lovells Melissa Hall, Founder and Principal Consultant, Statera Regulatory Consulting</li> <li>General information including how to select a predicate device</li> <li>Assembling the 510(k)</li> <li>eSTAR</li> </ul>

#### **Important Notice**



2:15 – 2:30 pm Break

2:30 – 3:15 pm The FDA Review Process • How it works at FDA

- FDA/industry interactions
- Refuse to Accept
- Submission Issue meetings
- FDA holds
- Interactive review
- Least Burdensome flag
- Current pilots

3:15 – 3:30 pm Break

3:30 – 4:00 pm

## **CDRH Ombudsman's Office**

- Roles & Responsibilities
- Appeals Process

#### **Important Notice**



# Feb 4, 2025

8:30 – 9:00 am	Continental Breakfast
9:00 – 10:15 am	<ul> <li>Clearance: Launch and After</li> <li>Tony Blank, Senior Director of Regulatory Affairs, AtriCure</li> <li>What clearance does and does not mean</li> <li>Promotional practices for 510(k) devices <ul> <li>FDA</li> <li>FTC</li> </ul> </li> <li>Complaint Handling and MDRs</li> <li>When to File a New 510(k) for Device Modifications</li> <li>Catch-up 510(k)s</li> </ul>
10:15 – 10:30 am	Break
10:30 – 11:00 am	<ul> <li>Definition of a De Novo</li> <li>Final Rule on De Novo</li> <li>When De Novo is used</li> <li>Differentiation from 510(k)</li> </ul>
11:00 – 11:30 am	<ul> <li>Regulatory Strategy for De Novo</li> <li>Key eligibility criteria</li> <li>Benefit-risk analysis</li> </ul>
11:30 am – 12:00 pm	<ul> <li>Preparing the De Novo Submission</li> <li>Content</li> <li>Assembling the submission</li> </ul>
12:00 – 1:00 pm	Networking Lunch
1:00 – 1:30 pm	<ul> <li>FDA Review Process for De Novo</li> <li>Use of Pre-Submission meeting</li> <li>Rationale for De Novo</li> <li>Clinical Protocols</li> <li>Special Controls</li> <li>Benefit-Risk Considerations</li> </ul>
1:30 – 2:00 pm	<ul> <li>Maintenance of a Granted De Novo</li> <li>Post-market requirements</li> <li>Classification Order</li> <li>De Novo database, granting order, decision summary</li> <li>Use as a predicate</li> <li>Making changes to granted De Novo device</li> </ul>

## **Important Notice**



 2:00 – 2:15 pm
 Break

 2:15 – 4:15 pm
 Applied Learning and Breakout Discussions

 \* In person participants, only
 • 510(k) & De Novo Recap
 • Facilitated Breakout Group Deep Dive - Hypothetical Case Studies & Key Takeaways
 • Regroup for Q&A

4:15 pm Adjournment

## **Important Notice**